Search Results
Jan 05, 2026, 19:00 ET ASUS Republic of Gamers Presents Next-Gen Gaming Innovations, Commemorates 20 Years of Gaming Excellence at CES 2026
1 x Type C, support TBT4 DP2.1+ PD3.0 (100W) 1 x Type-C support USB3.2 Gen2 DP2.1+PD3.0 (100W) 2 x USB3.2 Gen2 Type-A
More news about: ASUS Computer International
Jan 05, 2026, 08:30 ET MetaVia Reports Positive Statistically Significant Results from Its Phase 1b Clinical Trial of DA-1726 In Metabolic Disease - Demonstrating Strong Glycemic Response, Significant Direct Hepatic Effects, Robust Weight Loss and Favorable Safety Profile
development."The Phase 1 trial was a randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, PK, and pharmacodynamics (PD) of single and multiple ascending doses of DA-1726 in obese but otherwise healthy adults with a body mass index (BMI) of 30–45 kg/m². Nine subjects in
More news about: MetaVia Inc.
Jan 05, 2026, 08:05 ET SynuSight Biotech, ABLi Therapeutics and XingImaging Announce Strategic Collaboration to Implement Alpha-Synuclein PET Imaging into Clinical Trials Evaluating Risvodetinib as a Disease-modifying Therapy for Parkinson's disease
establishing an integrated framework for comprehensive evaluation of the therapeutic effects of risvodetinib in PD. ABLi plans to implement FD4 in two clinical trials in 2026. The first, ABILITY-PD, plans to re-enroll the 120 participants in the Phase 2a 201 Trial completed in 4Q24 to measure the effect
More news about: SynuSight Biotech
Jan 05, 2026, 08:00 ET AUKEY Introduces MagFusion DeskHive 5X Pro, Redefining Desktop Charging at CES 2026
protocols, ensuring rapid and efficient power delivery to a wide range of popular devices. Among its wired outputs, the USB-C1 port delivers up to 140W PD 3.1 fast charging, meeting the demands of power-hungry laptops.The wireless charging stand features a durable aluminum-alloy hinge
More news about: AUKEY
Jan 05, 2026, 07:00 ET 科倫博泰ITGB6 ADC SKB105臨床試驗申請獲NMPA批准
SKB118(亦稱CR-001)SKB118/CR-001是一款四價雙特異性抗體，目前正開發用於治療實體瘤。其結合了腫瘤學中兩種互補且經過驗證的作用機制——PD-1和VEGF阻斷，其中對PD-1檢查點的抑制可恢復T細胞識別和摧毀腫瘤細胞的能力，而VEGF阻斷可減少對腫瘤細胞的血液供應並抑制腫瘤生長。在臨床前研究中，SKB118/CR-001在VEGF存在的情況下顯示出提升 PD-1 的結合和信號阻斷能力的協同藥理作用，並具有強大的抗腫瘤活性。SKB118/CR-001的抗VEGF 活性還可能使腫瘤部位的血管正常化，有望提高聯合療法(尤其與ADC
More news about: 科倫博泰
Jan 05, 2026, 07:00 ET Kelun-Biotech Receives Investigational New Drug Approval for ITGB6-Targeted ADC SKB105 from the NMPA
antibody being developed for the treatment of solid tumors that combines two complementary, validated mechanisms in oncology via a blockade of PD-1 and VEGF. PD-1 checkpoint inhibition is aimed at restoring T cells' ability to recognize and destroy tumor cells, and blocking VEGF is intended for reducing
More news about: Kelun-Biotech
Jan 05, 2026, 04:27 ET Kelun-Biotech Announces Breakthrough Therapy Designation Granted in China for Sacituzumab Tirumotecan (sac-TMT) in Combination with Immunotherapy Pembrolizumab for First-Line Treatment of PD-L1-Positive NSCLC
systemic chemotherapy in June 2023;first-line treatment of unresectable locally advanced, recurrent or metastatic PD-L1 negative TNBC in March 2024;In combination with anti-PD-L1 monoclonal antibody tagitanlimab for the first-line treatment of locally advanced or metastatic non-squamous NSCLC
More news about: Kelun-Biotech
Jan 05, 2026, 02:21 ET Energizer Portable Power Series Delivers Standout Black Friday Performance in the U.S.
10,000mAhA travel-ready design combining 15W magnetic wireless charging with 20W PD fast output in a slim, portable form.QM5081PQ – 5,000mAhUltra-thin at just 0.35 inches, offering 15W wireless and 20W PD fast charging for everyday portability.Ultimate 3-Device Charging
More news about: TennRich International Corp.
Jan 04, 2026, 19:00 ET "MemorAiLink® Show Up" at CES 2026：Etron Tech Advances Edge AI and Robotics through On-Device Innovation
Etron's EJ732 series has successfully achieved USB-IF certification as a USB PD 3.2 DRP controller. Featuring a three-in-one full-end integration design covering host, device, and cable, it represents the industry's most complete USB PD 3.2 control platform. The EJ732 not only supports up to 240W (48V/5A) Extended
More news about: Etron Technology
Dec 31, 2025, 20:32 ET TennRich étend l'écosystème de l'alimentation portable Energizer® à toute l'Europe avec une disponibilité immédiate des stocks
haut rendement conçues pour les modes de vie actuels où les déplacements sont fréquents. Son cœur est une batterie externe USB-C à charge rapide de 20 W PD avec une prise secteur intégrée et des adaptateurs de voyage interchangeables — offrant une vitesse, une sécurité et une polyvalence fiables pour les
More news about: TennRich International Corp.
Dec 31, 2025, 08:41 ET TennRich erweitert Energizer® Portable Power Ecosystem in ganz Europa mit sofortiger Lagerverfügbarkeit
Energizer-Sortiment besteht aus leistungsstarken Ladelösungen, die für den heutigen mobilen Lebensstil entwickelt wurden. Das Herzstück ist eine 20-Watt-PD-Schnelllade-USB-C-Powerbank mit integrierter Steckdose und austauschbaren Reiseadaptern, die zuverlässige Ladegeschwindigkeit, Sicherheit und Vielseitigkeit
More news about: TennRich International Corp.
Dec 31, 2025, 07:06 ET TennRich expande el ecosistema de energía portátil Energizer® en Europa con disponibilidad inmediata de stock
soluciones de carga de alto rendimiento diseñadas para el estilo de vida actual, siempre en movimiento. Su núcleo es una batería externa USB-C de carga rápida PD de 20 W con una toma de CA integrada y adaptadores de viaje intercambiables, que ofrece velocidad fiable, seguridad y versatilidad para viajeros y profesionales
More news about: TennRich International Corp.
Dec 31, 2025, 04:41 ET TennRich Expands Energizer® Portable Power Ecosystem Across Europe with Immediate Stock Availability
LifestylesThe Energizer lineup is built around high-output charging solutions engineered for today's on-the-go lifestyles. At its core is a 20W PD fast-charge USB-C power bank with an integrated AC outlet and interchangeable travel adapters—delivering reliable speed, safety, and versatility for
More news about: TennRich International Corp.
Dec 31, 2025, 01:00 ET UGREEN Launches Fast-Charging Power Kit Under the Theme "Stay Connected, Stay Together" for Festive Celebrations in the Middle East
keys, bags, and other essentials. Users praise the simple setup and smooth integration with Apple's Find My network.UGREEN USB-C to USB-C PD Fast Charging Cable 60W for reliable high-speed charging across different devices. One UAE customer described it as an "excellent product overall"
More news about: UGREEN
Dec 30, 2025, 09:15 ET Epicka to Debut World's First 140W Touchscreen Smart Universal Travel Adapter at CES 2026
seamless coverage across 200+ countries and regions.Technical Specifications (Concise)Max Output: 45W (PD 3.0) / 65W (PD 3.0) / 140W (PD 3.1)Ports:45W & 65W: 5‑in‑1 (2 USB‑C, 2 USB‑A, 1 universal AC)140W: 6‑in‑1 (2 USB‑C, 2 USB‑A,
More news about: EPICKA INC.
Dec 29, 2025, 09:31 ET VAULT-M2 Hits Kickstarter: The EDC Organizer System Built to Adapt Like a Beast
https://shorturl.at/27EIqAbout PD EDCPD EDC is a London-based design team specializing in innovative everyday carry solutions. With multiple successful Kickstarter campaigns, the team's mission is to enable smarter, more flexible ways to carry, work, and explore.Media Contact:PD EDC TeamTel:
More news about: PD EDC
Dec 28, 2025, 21:24 ET Senhwa Biosciences Aims at Multi-Billion Dollar Global Market with CX-5461 Combined with ADC "Blockbuster" Therapy
Following its recent clinical collaboration with the multinational pharmaceutical company BeOne Medicines to explore combination therapy with its marketed PD-1 inhibitor in the challenging field of cold tumor treatment, Senhwa Biosciences, Inc. (TPEx: 6492, hereafter "Senhwa"), today announced another major
More news about: Senhwa Biosciences, Inc.
Dec 25, 2025, 03:45 ET China's First Domestic Anti-CTLA-4 Monoclonal Antibody, Innovent's TABOSUN® (Ipilimumab N01 Injection) Received NMPA Approval
injection) in China, is a PD-1 immunoglobulin G4 monoclonal antibody co-developed by Innovent and Eli Lilly and Company. Sintilimab is a type of immunoglobulin G4 monoclonal antibody, which binds to PD-1 molecules on the surface of T-cells, blocks the PD-1 / PD-Ligand 1 (PD-L1) pathway, and reactivates
More news about: Innovent Biologics
Dec 24, 2025, 08:55 ET Jason Zhu, PDG de Henlius, prononcera une allocution lors de la conférence JPM 2026
produit exclusif HANSIZHUANG (anticorps monoclonal anti-PD-1) comme base fondamentale. À ce jour, les produits lancés par la société comprennent HANSIZHUANG (serplulimab, nom commercial : Hetronifly® en Europe), le premier anticorps monoclonal anti-PD-1 au monde pour le traitement de première intention
More news about: Henlius
Dec 24, 2025, 08:54 ET El consejero delegado de Henlius, Dr. Jason Zhu, realizará una presentación magistral en JPM 2026
explorando terapias combinadas inmunooncológicas con HANSIZHUANG (anti-PD-1 mAb) patentado como base. Hasta la fecha, los productos lanzados por la compañía incluyen HANSIZHUANG (serplulimab, nombre comercial: Hetronifly® en Europa), el primer mAb anti-PD-1 del mundo para el tratamiento de primera línea de SCLC;
More news about: Henlius
Dec 24, 2025, 06:56 ET Dr. Jason Zhu, Geschäftsführer von Henlius, hält eine Grundsatzrede auf der JPM 2026
Kombinationstherapien mit dem firmeneigenen HANSIZHUANG (Anti-PD-1 mAb) als Grundgerüst fortgesetzt. Zu den bisher von dem Unternehmen eingeführten Produkten gehören HANSIZHUANG (Serplulimab, Handelsname: Hetronifly® in Europa), der weltweit erste Anti-PD-1-mAb zur Erstlinienbehandlung von SCLC, HANQUYOU
More news about: Henlius
Dec 23, 2025, 09:05 ET Henlius CEO Dr. Jason Zhu to Deliver a Keynote Presentation at JPM 2026
immuno-oncology combination therapies with proprietary HANSIZHUANG (anti-PD-1 mAb) as the backbone. To date, the company's launched products include HANSIZHUANG (serplulimab, trade name: Hetronifly® in Europe), the world's first anti-PD-1 mAb for the first-line treatment of SCLC, HANQUYOU (trastuzumab,
More news about: Henlius
Dec 23, 2025, 08:53 ET Henlius CEO Dr. Jason Zhu to Deliver a Keynote Presentation at JPM 2026
immuno-oncology combination therapies with proprietary HANSIZHUANG (anti-PD-1 mAb) as the backbone. To date, the company's launched products include HANSIZHUANG (serplulimab, trade name: Hetronifly® in Europe), the world's first anti-PD-1 mAb for the first-line treatment of SCLC, HANQUYOU (trastuzumab,
More news about: Henlius
Dec 23, 2025, 07:00 ET Senhwa Biosciences Highlights AI-Validated Oncology Platform and Strategic Clinical Collaborations Targeting Next-Generation Immuno-Oncology products at Its 2025 Annual Investor Conference
collaboration with BeOne Medicines to evaluate Senhwa's lead candidate, Pidnarulex (CX-5461), in combination with BeOne's commercially approved, best-in-class PD-1 inhibitor tislelizumab. The initial focus of the collaboration includes pancreatic cancer and advanced solid tumors, including immunotherapy-resistant
More news about: Senhwa Biosciences, Inc.
Dec 23, 2025, 00:03 ET Fapon Biopharma Publishes Pioneering Research in Cell Reports Medicine on FP008, an anti-PD 1 X IL-10M Fusion Protein for Cancer Immunotherapy
advanced solid tumors refractory to or relapsed from PD-1/PD-L1 checkpoint inhibitors.Reference: Gu et al., Cell Reports Medicine(2025). "An innovative engineered IL-10 monomer strengthens T cell-mediated anti-tumor responses through anti-PD-1 cis-delivery." DOI: doi.org/10.1016/j.xcrm.2025.102515
More news about: Fapon Biopharma